Literature DB >> 24895461

Influence of biospecimen variables on proteomic biomarkers in breast cancer.

Funda Meric-Bernstam1, Argun Akcakanat2, Huiqin Chen3, Aysegul Sahin4, Emily Tarco2, Selin Carkaci5, Beatriz E Adrada6, Gopal Singh2, Kim-Anh Do3, Zerzhinski M Garces2, Elizabeth Mittendorf7, Gildy Babiera7, Isabelle Bedrosian7, Rosa Hwang7, Savitri Krishnamurthy4, William F Symmans4, Ana Maria Gonzalez-Angulo8, Gordon B Mills9.   

Abstract

BACKGROUND: PI3K/Akt/mTOR signaling is being actively pursued as a therapeutic target for breast cancer. We sought to determine if tumor heterogeneity and biospecimen variables affect the evaluation of PI3K/Akt/mTOR pathway markers.
METHODS: Intraoperative image-guided core-needle biopsies (CNB), and central and peripheral surgical tumor specimens were prospectively collected in 53 patients with invasive breast cancer. Specimens were assessed with reverse-phase protein arrays (RPPA) and immunohistochemistry (IHC).
RESULTS: There was a moderate or strong correlation between the expression of 149 (97%) of the 154 different RPPA markers in the center and periphery. Correlation was higher for smaller tumors, in patients who did not undergo neoadjuvant therapy, and with shorter cold ischemia time. Of 154 markers, 132 (86%) were not statistically different between the center and periphery, and 97 (63%) were not different between the CNB and the surgical specimen (average of the central and peripheral specimen). pAkt S473 and PTEN had a significant correlation between central and peripheral specimens, and between CNB and surgical specimen. However, pAkt S473, pS6 S235/236, and pS6 240/244 levels were significantly higher in CNB than the central specimens both by RPPA and by IHC.
CONCLUSIONS: Most individual proteomic biomarkers studied do not have significant intratumoral heterogeneity. However, protein and phosphoprotein levels are affected by biospecimen type and other preanalytic variables. PI3K pathway activation is greater in CNB compared with postexcision surgical samples suggesting a potential loss of phosphorylation during surgical manipulation, or with cold ischemia of surgical specimens. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24895461      PMCID: PMC4112583          DOI: 10.1158/1078-0432.CCR-13-1507

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  23 in total

1.  Non-parametric quantification of protein lysate arrays.

Authors:  Jianhua Hu; Xuming He; Keith A Baggerly; Kevin R Coombes; Bryan T J Hennessy; Gordon B Mills
Journal:  Bioinformatics       Date:  2007-06-28       Impact factor: 6.937

2.  Effects of tissue handling on RNA integrity and microarray measurements from resected breast cancers.

Authors:  Christos Hatzis; Hongxia Sun; Hui Yao; Rebekah E Hubbard; Funda Meric-Bernstam; Gildy V Babiera; Yun Wu; Lajos Pusztai; W Fraser Symmans
Journal:  J Natl Cancer Inst       Date:  2011-10-27       Impact factor: 13.506

3.  Stability of phosphoprotein as a biological marker of tumor signaling.

Authors:  Amanda F Baker; Tomislav Dragovich; Nathan T Ihle; Ryan Williams; Cecilia Fenoglio-Preiser; Garth Powis
Journal:  Clin Cancer Res       Date:  2005-06-15       Impact factor: 12.531

4.  Role for intraoperative margin assessment in patients undergoing breast-conserving surgery.

Authors:  Neslihan Cabioglu; Kelly K Hunt; Aysegul A Sahin; Henry M Kuerer; Gildy V Babiera; S Eva Singletary; Gary J Whitman; Merrick I Ross; Frederick C Ames; Barry W Feig; Thomas A Buchholz; Funda Meric-Bernstam
Journal:  Ann Surg Oncol       Date:  2007-01-28       Impact factor: 5.344

5.  Glioblastoma cell enrichment is critical for analysis of phosphorylated drug targets and proteomic-genomic correlations.

Authors:  Claudius Mueller; Ana C deCarvalho; Tom Mikkelsen; Norman L Lehman; Valerie Calvert; Virginia Espina; Lance A Liotta; Emanuel F Petricoin
Journal:  Cancer Res       Date:  2013-12-17       Impact factor: 12.701

6.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.

Authors:  Marco Gerlinger; Andrew J Rowan; Stuart Horswell; James Larkin; David Endesfelder; Eva Gronroos; Pierre Martinez; Nicholas Matthews; Aengus Stewart; Charles Swanton; M Math; Patrick Tarpey; Ignacio Varela; Benjamin Phillimore; Sharmin Begum; Neil Q McDonald; Adam Butler; David Jones; Keiran Raine; Calli Latimer; Claudio R Santos; Mahrokh Nohadani; Aron C Eklund; Bradley Spencer-Dene; Graham Clark; Lisa Pickering; Gordon Stamp; Martin Gore; Zoltan Szallasi; Julian Downward; P Andrew Futreal
Journal:  N Engl J Med       Date:  2012-03-08       Impact factor: 91.245

7.  Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer.

Authors:  Isabel F Pinhel; Fiona A Macneill; Margaret J Hills; Janine Salter; Simone Detre; Roger A'hern; Ashutosh Nerurkar; Peter Osin; Ian E Smith; Mitch Dowsett
Journal:  Breast Cancer Res       Date:  2010-09-28       Impact factor: 6.466

8.  Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer.

Authors:  Ana M Gonzalez-Angulo; Bryan T Hennessy; Funda Meric-Bernstam; Aysegul Sahin; Wenbin Liu; Zhenlin Ju; Mark S Carey; Simen Myhre; Corey Speers; Lei Deng; Russell Broaddus; Ana Lluch; Sam Aparicio; Powel Brown; Lajos Pusztai; W Fraser Symmans; Jan Alsner; Jens Overgaard; Anne-Lise Borresen-Dale; Gabriel N Hortobagyi; Kevin R Coombes; Gordon B Mills
Journal:  Clin Proteomics       Date:  2011-07-08       Impact factor: 3.988

9.  Distant metastasis occurs late during the genetic evolution of pancreatic cancer.

Authors:  Shinichi Yachida; Siân Jones; Ivana Bozic; Tibor Antal; Rebecca Leary; Baojin Fu; Mihoko Kamiyama; Ralph H Hruban; James R Eshleman; Martin A Nowak; Victor E Velculescu; Kenneth W Kinzler; Bert Vogelstein; Christine A Iacobuzio-Donahue
Journal:  Nature       Date:  2010-10-28       Impact factor: 49.962

10.  Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC).

Authors:  M Arnedos; A Nerurkar; P Osin; R A'Hern; I E Smith; M Dowsett
Journal:  Ann Oncol       Date:  2009-07-01       Impact factor: 32.976

View more
  24 in total

1.  Pre-surgical trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: a New York Cancer Consortium trial.

Authors:  K Kalinsky; J A Sparano; X Zhong; E Andreopoulou; B Taback; L Wiechmann; S M Feldman; P Ananthakrishnan; A Ahmad; S Cremers; A N Sireci; J R Cross; D K Marks; P Mundi; E Connolly; K D Crew; M A Maurer; H Hibshoosh; S Lee; D L Hershman
Journal:  Clin Transl Oncol       Date:  2018-05-07       Impact factor: 3.405

2.  Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors.

Authors:  Arvind Dasari; Alexandria Phan; Sanjay Gupta; Asif Rashid; Sai-Ching Jim Yeung; Kenneth Hess; Helen Chen; Emily Tarco; Huiqin Chen; Caimiao Wei; Kim Anh-Do; Daniel Halperin; Funda Meric-Bernstam; James Yao
Journal:  Endocr Relat Cancer       Date:  2015-04-21       Impact factor: 5.678

Review 3.  [Preanalytics and biobanking : Influence of preanalytical factors on tissue sample quality].

Authors:  K-F Becker; J Wipperfürth; E Herpel
Journal:  Pathologe       Date:  2018-07       Impact factor: 1.011

4.  Proteomic modulation in breast tumors after metformin exposure: results from a "window of opportunity" trial.

Authors:  K Kalinsky; T Zheng; H Hibshoosh; X Du; P Mundi; J Yang; S Refice; S M Feldman; B Taback; E Connolly; K D Crew; M A Maurer; D L Hershman
Journal:  Clin Transl Oncol       Date:  2016-06-15       Impact factor: 3.405

5.  Active monitoring of formaldehyde diffusion into histological tissues with digital acoustic interferometry.

Authors:  Daniel R Bauer; Benjamin Stevens; David Chafin; Abbey P Theiss; Michael Otter
Journal:  J Med Imaging (Bellingham)       Date:  2016-02-08

6.  A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors.

Authors:  Kurt W Evans; Erkan Yuca; Argun Akcakanat; Stephen M Scott; Natalia Paez Arango; Xiaofeng Zheng; Ken Chen; Coya Tapia; Emily Tarco; Agda K Eterovic; Dalliah M Black; Jennifer K Litton; Timothy A Yap; Debu Tripathy; Gordon B Mills; Funda Meric-Bernstam
Journal:  Clin Cancer Res       Date:  2017-11-01       Impact factor: 12.531

Review 7.  Using reverse-phase protein arrays as pharmacodynamic assays for functional proteomics, biomarker discovery, and drug development in cancer.

Authors:  Yiling Lu; Shiyun Ling; Apurva M Hegde; Lauren A Byers; Kevin Coombes; Gordon B Mills; Rehan Akbani
Journal:  Semin Oncol       Date:  2016-06-15       Impact factor: 4.929

8.  Differential Regulation and Targeting of Estrogen Receptor α Turnover in Invasive Lobular Breast Carcinoma.

Authors:  Sreeja Sreekumar; Kevin M Levine; Matthew J Sikora; Jian Chen; Nilgun Tasdemir; Dorothy Carter; David J Dabbs; Carolin Meier; Ahmed Basudan; David Boone; Priscilla F McAuliffe; Rachel C Jankowitz; Adrian V Lee; Jennifer M Atkinson; Steffi Oesterreich
Journal:  Endocrinology       Date:  2020-09-01       Impact factor: 4.736

9.  Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer.

Authors:  Argun Akcakanat; Xiaofeng Zheng; Christian X Cruz Pico; Tae-Beom Kim; Ken Chen; Anil Korkut; Aysegul Sahin; Vijaykumar Holla; Emily Tarco; Gopal Singh; Senthil Damodaran; Gordon B Mills; Ana Maria Gonzalez-Angulo; Funda Meric-Bernstam
Journal:  Clin Cancer Res       Date:  2021-03-29       Impact factor: 12.531

10.  Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes.

Authors:  Priscilla F McAuliffe; Kurt W Evans; Argun Akcakanat; Ken Chen; Xiaofeng Zheng; Hao Zhao; Agda Karina Eterovic; Takafumi Sangai; Ashley M Holder; Chandeshwar Sharma; Huiqin Chen; Kim-Anh Do; Emily Tarco; Mihai Gagea; Katherine A Naff; Aysegul Sahin; Asha S Multani; Dalliah M Black; Elizabeth A Mittendorf; Isabelle Bedrosian; Gordon B Mills; Ana Maria Gonzalez-Angulo; Funda Meric-Bernstam
Journal:  PLoS One       Date:  2015-09-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.